ORBIMED ADVISORS LLC

Q2 2025 13F-HR Detailed Holdings

Location
New York, NY
Holdings as of
6/30/2025
Date filed
8/14/2025
Form type
13F-HR
Num holdings
103
Total value ($000)
$4,004,111
Net value change ($000)
-190,535 (-4.5%)
New positions
14
Sold out positions
23
Turnover %
14.5%
Sector allocation + QoQ delta (equities-only)

Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings

You are on the SEC detailed breakdown page. Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields), and are not merged like the standard holdings view. Switch to aggregated holdings.

Snapshot: Change Analysis

Compared to Q1 2025
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
CAI 81,091 NEW
SPRY 40,366 38.7%
ROIV 31,324 NEW
UPB 27,671 79.4%
SION 25,527 65.9%
NTRA 22,904 29.6%
EW 22,544 20.3%
THC 19,297 30.9%
CTMX 19,208 NEW
BSX 18,370 6.5%
Top Reduces (Value $000, Stocks/ETFs)
EWTX -127,031 -38.4%
PFE -97,564 -100.0%
IONS -76,636 -100.0%
NBIX -48,251 -46.7%
TMO -45,336 -70.6%
SpringWorks Therapeutics, Inc. -41,932 -100.0%
XTNT -34,364 -100.0%
TARS -25,566 -76.1%
CYTK -25,071 -41.3%
ITGR -24,887 -31.8%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 27,469 (0.7% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type Discretion Other Manager Sole Shared None

Other Managers

Num Name File Number
1 ORBIMED CAPITAL LLC 028-10410